Dyadic International, Inc. (NASDAQ:DYAI) CEO Mark A. Emalfarb sold 23,000 shares of the business’s stock in a transaction on Wednesday, June 9th. The stock was sold at an average price of $3.72, for a total value of $85,560.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Shares of DYAI stock opened at $3.74 on Friday. Dyadic International, Inc. has a 1 year low of $3.34 and a 1 year high of $10.98. The stock’s fifty day simple moving average is $4.36. The firm has a market cap of $103.05 million and a price-to-earnings ratio of -11.00.
Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings results on Monday, March 29th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.01. Dyadic International had a negative return on equity of 35.81% and a negative net margin of 595.37%. As a group, research analysts expect that Dyadic International, Inc. will post -0.4 EPS for the current fiscal year.
Dyadic International Company Profile
Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.
Featured Article: How does a security become overbought?
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.